September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

William Cadden: Risk–Benefit Considerations in Atrial Fibrillation

William Cadden/LinkedIn

Apr 24, 2026, 07:13

William Cadden: Risk–Benefit Considerations in Atrial Fibrillation

William Cadden, Director of Medical Device Partnerships at Radcliffe Group, shared a post on LinkedIn:

“At ACC26, Dr Devi G Nair and Dr Vivek Reddy discussed the implications of the late-breaking CHAMPION-AF data, focusing on a central clinical question: how should we weigh stroke risk against bleeding reduction?

The data suggest a modest absolute increase in ischaemic stroke and systemic embolism with a device-based strategy, offset by a substantial reduction in clinically relevant bleeding.

Interpreting this balance is not straightforward and depends on how different endpoints are valued in practice.

A key part of the discussion explored whether all bleeding events should be considered equal, particularly when ‘clinically relevant non-major’ bleeding is included alongside more severe outcomes.

Similarly, the role of procedure-related complications within composite endpoints remains an important consideration when assessing overall benefit.

Ultimately, the conversation reinforces that this is not a one-size-fits-all decision.

The relative importance of stroke prevention versus bleeding avoidance will vary between patients, and careful selection remains essential when considering first-line left atrial appendage closure versus continued anticoagulation.

As longer-term follow-up becomes available, these trade-offs will become clearer and further inform clinical decision-making.”

Proceed to the video attached to the post.

Stay updated with Hemostasis Today.